Tilray Brands Inc (NASDAQ:TLRY) stock fell 0.31% (As on October 11, 11:15:47 AM UTC-4, Source: Google Finance) after the company’s fiscal first quarter sales missed estimates. Its net loss improved by 38% to a loss of $34.7 million from a loss of $55.9 million in the previous year’s quarter. The gross profit increased by 35% and gross margin increased by over 500 basis points compared to the prior-year quarter. Adjusted EBITDA was $9.3 million, compared to $10.7 million in the prior year quarter.  Cash flow used in operations was $35.3 million, compared to $15.8 million in the prior year quarter. Adjusted free cash flow was negative $39.5 million, compared to negative $6.3 million in the prior year quarter

Moreover, the beverage business, including craft beer, spirits, and the new non-alc beers and other non-alcoholic drinks grew 132% in net revenue year over year. The company has recently launched a new beverage division called Tilray Alternative Beverages, focused on fueling key markets across the U.S., with innovative federally legal, hemp derivative Delta 9, THC branded, and branded products.

Meanwhile, the company is studying plans for a potential consolidation of its US breweries. In the three months to the end of August, the net revenue Tilray generated from its beverage-alcohol division, including M&A, more than doubled, reaching $56m. The business accounted for 28% of Tilray’s group net revenue, up from 13% a year earlier. Tilray disclosed the “adjusted gross margin” from the division as 41%, down from 56% a year ago. The company is looking to bring in a state-centred focus for the distribution of its brands, Simon explained. While Simon again said he believes Shock Top should be a national brand, he acknowledged that was not the case for all of Tilray’s craft beer range.

TLRY in the first quarter of FY 25 has reported the adjusted loss per share of 4 cents, beating the analysts’ estimates for the adjusted loss per share of 5 cents. The company had reported the adjusted revenue growth of 13 percent to $200 million in the first quarter of FY 25, missing the analysts’ estimates for revenue of $218.9 million. Sales from its cannabis business declined to $62.8 million from $70.3 million, contributing 31% of total revenue. Its German medical cannabis flower revenue increased by 50% following legalization in the nation.